World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
100
Citations
51998
World Ranking
8138
National Ranking
4217

Overview

Nancy L. Bartlett is affiliated with Washington University in St. Louis in the United States. Their research primarily spans the field of Medicine, with a strong focus on oncology and related subfields including Pathology and Forensic Medicine, Genetics, Pulmonary and Respiratory Medicine, and Radiology, Nuclear Medicine and Imaging.

The main topics of their work revolve around various aspects of lymphoma and cancer treatment, with significant emphasis on Lymphoma Diagnosis and Treatment, CAR-T Cell Therapy Research, and Chronic Lymphocytic Leukemia Research. Additional areas covered include CNS Lymphoma Diagnosis and Treatment, Monoclonal and Polyclonal Antibodies Research, Lung Cancer Treatments and Mutations, and Viral-associated cancers and disorders.

Recent notable publications by Nancy L. Bartlett include:

  • Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study (2022, The Lancet Oncology)
  • Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma (2022, New England Journal of Medicine)
  • The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (2021, Annals of Oncology)
  • CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas (2020, Blood)
  • 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1) (2023, Blood)

Nancy L. Bartlett has collaborated frequently with several researchers, including:

  • Brad S. Kahl
  • John P. Leonard
  • Lihua E. Budde
  • Ranjana H. Advani
  • Marcus P. Watkins

The researcher's work is published extensively in journals such as Blood, Clinical Lymphoma Myeloma & Leukemia, Journal of Clinical Oncology, Blood Advances, and Hematological Oncology. This distribution reflects focused contributions to hematology and oncology fields.

Best Publications

  • Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    Sattva S. Neelapu;Frederick L. Locke;Nancy L. Bartlett;Lazaros J. Lekakis

  • Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

    Frederick L Locke;Armin Ghobadi;Caron A Jacobson;David B Miklos

  • Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

    Roland Schmitz;George W. Wright;Da Wei Huang;Calvin A. Johnson

  • Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia

    Jan A. Burger;Alessandra Tedeschi;Paul M. Barr;Tadeusz Robak

  • Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

    Anas Younes;Ajay K. Gopal;Scott E. Smith;Stephen M. Ansell

  • Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

    Thomas E. Witzig;Leo I. Gordon;Fernando Cabanillas;Myron S. Czuczman

  • Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

    Anas Younes;Nancy L Bartlett;John P Leonard;Dana A Kennedy

  • Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

    Barbara Pro;Ranjana Advani;Pauline Brice;Nancy L. Bartlett

  • Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

    Jennifer A Woyach;Amy S Ruppert;Nyla A Heerema;Weiqiang Zhao

  • CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.

    Ranjana Advani;Ian Flinn;Leslie Popplewell;Andres Forero

  • Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

    Joseph M. Connors;Wojciech Jurczak;David J. Straus;Stephen M. Ansell

  • Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

    Owen A. O'Connor;Barbara Pro;Lauren Pinter-Brown;Nancy Bartlett

  • Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

    Frederick L. Locke;Sattva S. Neelapu;Nancy L. Bartlett;Tanya Siddiqi

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • Barriers to Clinical Trial Participation by Older Women With Breast Cancer

    M. Margaret Kemeny;Bercedis L. Peterson;Alice B. Kornblith;Hyman B. Muss

  • Ibrutinib Combined With Bendamustine and Rituximab Compared With Placebo, Bendamustine, and Rituximab for Previously Treated Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma (HELIOS): A Randomised, Double-Blind, Phase 3 Study

    Asher Chanan-Khan;Paula Cramer;Fatih Demirkan;Graeme Fraser

  • Stanford V and Radiotherapy for Locally Extensive and Advanced Hodgkin’s Disease: Mature Results of a Prospective Clinical Trial

    Sandra J. Horning;Richard T. Hoppe;Sheila Breslin;Nancy L. Bartlett

  • Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial

    Gregory A. Wiseman;Leo I Gordon;Pratik S. Multani;Thomas E. Witzig

  • Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin

    Steven M. Horwitz;Ranjana H. Advani;Nancy L. Bartlett;Eric D. Jacobsen

  • Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)

    Leo I. Gordon;Fangxin Hong;Richard I. Fisher;Nancy L. Bartlett

Frequent Co-Authors

Ranjana H. Advani
Ranjana H. Advani Stanford University
John P. Leonard
John P. Leonard Cornell University
Bruce D. Cheson
Bruce D. Cheson Georgetown University
Jonathan W. Friedberg
Jonathan W. Friedberg University of Rochester
Leo I. Gordon
Leo I. Gordon Northwestern University
Eric D. Hsi
Eric D. Hsi Cleveland Clinic
Julie M. Vose
Julie M. Vose University of Nebraska Medical Center
Todd A. Fehniger
Todd A. Fehniger Washington University in St. Louis
Joseph M. Connors
Joseph M. Connors University of British Columbia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As you consider a career in medicine, it's important to explore various online degree options and pathways that can help you achieve your goals. Many students are now looking for flexible and affordable alternatives to traditional on-campus programs, especially in nursing and healthcare.

One of the most common questions is how much is online nursing school? Tuition can vary widely, but there are many reputable and affordable programs available. If you already have your RN, pursuing the cheapest rn to bsn program lets you advance your education quickly and cost-effectively.

For those interested in advanced research or academic roles, consider phd in nursing online programs, which offer flexibility and in-depth training. If you hold a non-nursing bachelor’s degree but want to switch careers, direct entry msn programs for non-nurses online provide a fast-track route into nursing practice.

Exploring these options can help you find the right career pathway in the healthcare field, tailored to your background, budget, and future ambitions.

Best Scientists Citing Nancy L. Bartlett

Trending Scientists